Bayer said today it has agreed to acquire BlueRock Therapeutics for up to $600 million in a deal designed to catapult the buyer into leadership in cell therapies, nearly three years after joining with healthcare investment firm Versant Ventures to launch the company.
{iframe}https://www.genengnews.com/news/bayer-to-acquire-bluerock-therapeutics-for-up-to-600m-with-cell-therapy-pipeline-in-mind/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20190809&oly_enc_id=1673D8247356B7U{/iframe}